Scarica l'app Stockscreener
68.14
3.35%
2.21
Dopo l'orario di chiusura:
68.25
0.11
+0.16%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CRSP Giù?
Forum
Previsione
Precedente Chiudi:
$65.93
Aprire:
$67.055
Volume 24 ore:
1.38M
Relative Volume:
0.48
Capitalizzazione di mercato:
$5.88B
Reddito:
$170.10M
Utile/perdita netta:
$-239.59M
Rapporto P/E:
-24.34
EPS:
-2.8
Flusso di cassa netto:
$-191.20M
1 W Prestazione:
+23.58%
1M Prestazione:
+49.59%
6M Prestazione:
+54.06%
1 anno Prestazione:
+19.15%
Intervallo 1D:
$67.01
$68.72
Intervallo di 1 settimana:
$54.80
$71.13
Portata 52W:
$30.04
$71.13
Crispr Therapeutics Ag Stock (CRSP) Company Profile
Nome
Crispr Therapeutics Ag
Settore
Industria
Telefono
(617) 315-4600
Indirizzo
BAARERSTRASSE 14, ZUG
Confronta CRSP con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CRSP
Crispr Therapeutics Ag
|
68.14 | 5.69B | 170.10M | -239.59M | -191.20M | -2.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
476.95 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.39 | 60.56B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.64 | 42.41B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
575.42 | 34.96B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.83 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Crispr Therapeutics Ag Stock (CRSP) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-14 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2025-02-12 | Aggiornamento | TD Cowen | Sell → Hold |
| 2025-02-03 | Iniziato | H.C. Wainwright | Buy |
| 2024-08-06 | Reiterato | Needham | Buy |
| 2024-08-02 | Iniziato | Rodman & Renshaw | Buy |
| 2024-06-28 | Ripresa | Guggenheim | Neutral |
| 2024-02-15 | Iniziato | Wolfe Research | Peer Perform |
| 2023-12-11 | Downgrade | TD Cowen | Market Perform → Underperform |
| 2023-10-17 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2023-09-27 | Iniziato | Mizuho | Buy |
| 2023-08-17 | Aggiornamento | Citigroup | Neutral → Buy |
| 2023-05-30 | Iniziato | William Blair | Outperform |
| 2023-04-13 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-03-21 | Iniziato | Bernstein | Mkt Perform |
| 2023-03-17 | Iniziato | Bryan Garnier | Buy |
| 2023-03-07 | Iniziato | Robert W. Baird | Neutral |
| 2022-10-11 | Iniziato | Morgan Stanley | Underweight |
| 2022-08-09 | Downgrade | Barclays | Overweight → Equal Weight |
| 2022-06-23 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-06-17 | Iniziato | BMO Capital Markets | Outperform |
| 2022-04-28 | Iniziato | Credit Suisse | Neutral |
| 2021-12-07 | Iniziato | Cowen | Market Perform |
| 2021-10-19 | Iniziato | SVB Leerink | Outperform |
| 2021-06-14 | Aggiornamento | Citigroup | Sell → Neutral |
| 2021-04-21 | Aggiornamento | Jefferies | Hold → Buy |
| 2021-03-04 | Iniziato | JMP Securities | Mkt Outperform |
| 2020-12-10 | Reiterato | Chardan Capital Markets | Buy |
| 2020-12-10 | Downgrade | Jefferies | Buy → Hold |
| 2020-12-10 | Reiterato | Needham | Buy |
| 2020-12-07 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2020-10-23 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2020-10-05 | Iniziato | BofA Securities | Buy |
| 2020-07-28 | Reiterato | Needham | Buy |
| 2020-07-14 | Iniziato | SunTrust | Buy |
| 2020-06-15 | Reiterato | Canaccord Genuity | Buy |
| 2020-03-05 | Iniziato | Stifel | Hold |
| 2020-02-03 | Downgrade | Evercore ISI | Outperform → In-line |
| 2019-11-19 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2019-11-12 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2019-08-01 | Iniziato | Jefferies | Buy |
| 2019-07-26 | Iniziato | Canaccord Genuity | Buy |
| 2019-06-10 | Iniziato | ROTH Capital | Buy |
| 2019-04-12 | Iniziato | Evercore ISI | Outperform |
| 2019-03-14 | Iniziato | William Blair | Mkt Perform |
| 2019-01-28 | Downgrade | Goldman | Buy → Neutral |
| 2019-01-22 | Downgrade | Citigroup | Neutral → Sell |
Mostra tutto
Crispr Therapeutics Ag Borsa (CRSP) Ultime notizie
Is CRISPR Therapeutics AG a good long term investmentRemarkably fast returns - Autocar Professional
CRISPR Therapeutics AG Stock Analysis and ForecastOutperformance with explosive growth - Autocar Professional
CRISPR Therapeutics (CRSP) Surges 71% Last Quarter With Inclusion In Russell Indices - simplywall.st
Crispr Therapeutics: Shares Are SoaringThis Could Be The Start Of Something Big (CRSP) - Seeking Alpha
What drives CRISPR Therapeutics AG stock priceExceptional trading results - Autocar Professional
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know - MSN
Private Advisor Group LLC Increases Stake in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
Research Analysts Set Expectations for CRSP Q2 Earnings - MarketBeat
Bank of America Cuts CRISPR Therapeutics (NASDAQ:CRSP) Price Target to $78.00 - MarketBeat
Crispr Therapeutics price target lowered to $78 from $79 at BofA - TipRanks
What analysts say about CRISPR Therapeutics AG stockDynamic profit expansion - jammulinksnews.com
CRISPR Therapeutics' Stock Surge: A Glimpse into the Future of Gene-Editing Investment - AInvest
CRISPR Therapeutics (NASDAQ:CRSP) Sees Unusually-High Trading VolumeTime to Buy? - MarketBeat
CRISPR Therapeutics Rises Amid Gene Editing Breakthroughs - StocksToTrade
CRISPR Stock (CRSP) Continues to Sizzle on Insider Deal - TipRanks
Insider Buying: CRISPR Therapeutics AG (NASDAQ:CRSP) Director Buys 989,812 Shares of Stock - MarketBeat
3 Monster Stocks in the Making to Buy Right Now - The Motley Fool
CRISPR Therapeutics (CRSP) Soars 18% After $51-Million Insider Trading - MSN
Q2 EPS Estimate for CRISPR Therapeutics Lifted by Analyst - MarketBeat
CRISPR Therapeutics AG (NASDAQ:CRSP) Receives $71.75 Average Price Target from Analysts - MarketBeat
Crispr Therapeutics AG Stock Soars Amid Insider Confidence - TipRanks
CRISPR Therapeutics AG (CRSP) Declines More Than Market: Some Information for Investors - MSN
Is It Worth Investing in CRISPR Therapeutics (CRSP) Based on Wall Street's Bullish Views? - MSN
CRISPR Therapeutics (NASDAQ:CRSP) Trading Down 5.7%What's Next? - MarketBeat
CRSP’s Astounding Gains: Should Investors Jump In? - timothysykes.com
CRISPR Therapeutics (CRSP) Surges after Director Buys over $51M Worth of Shares - TipRanks
Crispr stock soars after director buys $51.5 million in shares - Investing.com
CRISPR Therapeutics Breaks Ground with Promising Phase 1 Trial Advances - timothysykes.com
CRISPR Therapeutics (NASDAQ:CRSP) Hits New 52-Week High Following Insider Buying Activity - MarketBeat
Crispr director George buys $51.5M of shares (CRSP:NASDAQ) - Seeking Alpha
Crispr Therapeutics stock hits 52-week high at 62.32 USD - Investing.com
Director Makes Multi-Million Dollar Investment in Crispr Therapeutics AG! - TipRanks
Crispr Therapeutics Ag Azioni (CRSP) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
4.91%
0.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):